Human vitreous levels of cefamandole and moxalactam

Judith L. Axelrod, Richard M. Klein, Robert L. Bergen, Mohammed Z. Sheikh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We gave 2-g intravenous doses of either cefamandole or moxalactam to 22 patients before vitrectomy. At 1 1 2 to 2 1 2 hours after administration, cefamandole vitreous concentrations varied from 0.36 to 2.05 μg/ml (mean, 0.94 μg/ml). Individual levels above the minimum inhibitory concentration of cefamandole for 90% (MIC90) of Staphylococcus aureus were found in five of 11 patients. Levels above the MIC90 for S. epidermidis were found in only two of 11 samples. Vitreous concentrations above the MIC90 of cefamandole for common gram-negative pathogens were found in only two patients. Moxalactam concentrations in the vitreous varied from 1.1 to 4 μg/ml 30 minutes to six hours after administration. These levels were not above moxalactam's MIC90 for S. aureus or S. epidermidis but were many times higher than the MIC9o of moxalactam for Enterobacteriaceae excluding Pseudomonas.

Original languageEnglish (US)
Pages (from-to)684-687
Number of pages4
JournalAmerican Journal of Ophthalmology
Volume101
Issue number6
StatePublished - Jun 15 1986
Externally publishedYes

Fingerprint

Cefamandole
Moxalactam
Microbial Sensitivity Tests
Staphylococcus aureus
Vitrectomy
Enterobacteriaceae
Pseudomonas

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Axelrod, J. L., Klein, R. M., Bergen, R. L., & Sheikh, M. Z. (1986). Human vitreous levels of cefamandole and moxalactam. American Journal of Ophthalmology, 101(6), 684-687.

Human vitreous levels of cefamandole and moxalactam. / Axelrod, Judith L.; Klein, Richard M.; Bergen, Robert L.; Sheikh, Mohammed Z.

In: American Journal of Ophthalmology, Vol. 101, No. 6, 15.06.1986, p. 684-687.

Research output: Contribution to journalArticle

Axelrod, JL, Klein, RM, Bergen, RL & Sheikh, MZ 1986, 'Human vitreous levels of cefamandole and moxalactam', American Journal of Ophthalmology, vol. 101, no. 6, pp. 684-687.
Axelrod JL, Klein RM, Bergen RL, Sheikh MZ. Human vitreous levels of cefamandole and moxalactam. American Journal of Ophthalmology. 1986 Jun 15;101(6):684-687.
Axelrod, Judith L. ; Klein, Richard M. ; Bergen, Robert L. ; Sheikh, Mohammed Z. / Human vitreous levels of cefamandole and moxalactam. In: American Journal of Ophthalmology. 1986 ; Vol. 101, No. 6. pp. 684-687.
@article{a3b3aa66472f4cf29dcdc2d7e130af0c,
title = "Human vitreous levels of cefamandole and moxalactam",
abstract = "We gave 2-g intravenous doses of either cefamandole or moxalactam to 22 patients before vitrectomy. At 1 1 2 to 2 1 2 hours after administration, cefamandole vitreous concentrations varied from 0.36 to 2.05 μg/ml (mean, 0.94 μg/ml). Individual levels above the minimum inhibitory concentration of cefamandole for 90{\%} (MIC90) of Staphylococcus aureus were found in five of 11 patients. Levels above the MIC90 for S. epidermidis were found in only two of 11 samples. Vitreous concentrations above the MIC90 of cefamandole for common gram-negative pathogens were found in only two patients. Moxalactam concentrations in the vitreous varied from 1.1 to 4 μg/ml 30 minutes to six hours after administration. These levels were not above moxalactam's MIC90 for S. aureus or S. epidermidis but were many times higher than the MIC9o of moxalactam for Enterobacteriaceae excluding Pseudomonas.",
author = "Axelrod, {Judith L.} and Klein, {Richard M.} and Bergen, {Robert L.} and Sheikh, {Mohammed Z.}",
year = "1986",
month = "6",
day = "15",
language = "English (US)",
volume = "101",
pages = "684--687",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Human vitreous levels of cefamandole and moxalactam

AU - Axelrod, Judith L.

AU - Klein, Richard M.

AU - Bergen, Robert L.

AU - Sheikh, Mohammed Z.

PY - 1986/6/15

Y1 - 1986/6/15

N2 - We gave 2-g intravenous doses of either cefamandole or moxalactam to 22 patients before vitrectomy. At 1 1 2 to 2 1 2 hours after administration, cefamandole vitreous concentrations varied from 0.36 to 2.05 μg/ml (mean, 0.94 μg/ml). Individual levels above the minimum inhibitory concentration of cefamandole for 90% (MIC90) of Staphylococcus aureus were found in five of 11 patients. Levels above the MIC90 for S. epidermidis were found in only two of 11 samples. Vitreous concentrations above the MIC90 of cefamandole for common gram-negative pathogens were found in only two patients. Moxalactam concentrations in the vitreous varied from 1.1 to 4 μg/ml 30 minutes to six hours after administration. These levels were not above moxalactam's MIC90 for S. aureus or S. epidermidis but were many times higher than the MIC9o of moxalactam for Enterobacteriaceae excluding Pseudomonas.

AB - We gave 2-g intravenous doses of either cefamandole or moxalactam to 22 patients before vitrectomy. At 1 1 2 to 2 1 2 hours after administration, cefamandole vitreous concentrations varied from 0.36 to 2.05 μg/ml (mean, 0.94 μg/ml). Individual levels above the minimum inhibitory concentration of cefamandole for 90% (MIC90) of Staphylococcus aureus were found in five of 11 patients. Levels above the MIC90 for S. epidermidis were found in only two of 11 samples. Vitreous concentrations above the MIC90 of cefamandole for common gram-negative pathogens were found in only two patients. Moxalactam concentrations in the vitreous varied from 1.1 to 4 μg/ml 30 minutes to six hours after administration. These levels were not above moxalactam's MIC90 for S. aureus or S. epidermidis but were many times higher than the MIC9o of moxalactam for Enterobacteriaceae excluding Pseudomonas.

UR - http://www.scopus.com/inward/record.url?scp=0022539367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022539367&partnerID=8YFLogxK

M3 - Article

C2 - 3717251

AN - SCOPUS:0022539367

VL - 101

SP - 684

EP - 687

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -